Cornerstone is a privately held pharmaceutical company uniquely focused on the discovery and development of innovative cancer therapies that exploit the metabolic pathways that are common to different cancer types but different from normal cells and tissues.
They believe that their approach, i.e. understanding and addressing what is similar to cancer types rather than the differences of each, offers the best opportunity to have a profound impact on the clinical treatment of a variety of cancers.
Current Team (10)Update
Vice President and General Counsel
Vice President and Chief Financial Officer
Director of Intellectual Property
President & Chief Operating Officer
Funding Rounds (4) - $19.2MUpdate
Board Members and Advisors (3)Update
1 Duncan Drive
Cranbury, NJ 08512